TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32493098

Group type: EXPERIMENTAL
Intervention: QFT-Plus test for LTBI
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Older than 50 years
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: From the Philippines
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: From the Indian subcontinent
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Working as a nurse
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Allied health profession
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Radiology technician
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Working in the emergency room
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Working in the intensive care unit
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Age group older than 50 years
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Known TB exposure
Number of subjects: 3024

Group type: EXPERIMENTAL
Intervention: Not receiving BCG at birth
Number of subjects: 3024
Study: 32750703

Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: X-ray therapy (XRT)
Number of subjects: 84
Study: 33044178

Group type: EXPERIMENTAL
Intervention: HP‐EH‐EVOO (50 mL/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MP‐EVOO (50 mL/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MeDi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HP‐EH‐EVOO and MP‐EVOO
Number of subjects: 0
Study: 35341692

Group type: EXPERIMENTAL
Intervention: Customized integration titanium mesh (CITM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional titanium plates
Number of subjects: 20
Study: 32671559

Group type: EXPERIMENTAL
Intervention: MAF group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Activator group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 34
Study: 35322709

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, delivered over the left dorsolateral prefrontal cortex, 100% rest motor threshold)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS (same protocol as active but without magnetic stimulation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40
Study: 35389559

Group type: EXPERIMENTAL
Intervention: Prosthesis buccal emergence profile design based on the buccal mucosal W/H ratio (Test Group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Original emergence profile of the healing abutment (Control Group)
Number of subjects: 21
Study: 34051880

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study: 33988836

Group type: EXPERIMENTAL
Intervention: Multi-vessel coronary artery disease (MV-CAD)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Single-vessel coronary artery disease (SV-CAD)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 2-vessel disease
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 3-vessel disease
Number of subjects: 507
Study: 34491014

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMX + MET after SRP
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AMX + MET during SRP
Number of subjects: 42
Study: 32557991

Group type: EXPERIMENTAL
Intervention: Low AM (200 mg/kg BW)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Middle AM (400 mg/kg BW)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High AM (800 mg/kg BW)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON (0 mg/kg BW)
Number of subjects: 16
Study: 35869267

Group type: EXPERIMENTAL
Intervention: Oral selinexor 60 mg twice weekly (days 1–24) with standard chemotherapy (3 + 7)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cytarabine 1000 mg/m2 twice daily, days 1–6 with selinexor
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard chemotherapy (3 + 7) without selinexor
Number of subjects: 102
Study: 33952438

Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure wound therapy (NPWT)
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 2035
Study: 34260849

Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus Etesevimab (2800 mg each, administered together)
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus Etesevimab
Number of subjects: 1035
Study: 33308472

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 564

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 564
Study: 32752924

Group type: EXPERIMENTAL
Intervention: Voluntary assisted dying training (9 modules including an assessment module)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment module (30 questions with a pass mark of 90%)
Number of subjects: 0
Study: 32121016

Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 13% inulin (Y13)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 3% inulin (Y3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 7% inulin (Y7)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Coffee-cascara yogurt without inulin (Y0)
Number of subjects: 45
Study: 36088731

Group type: EXPERIMENTAL
Intervention: Person-centered bowel program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual management (control group)
Number of subjects: 50
Study: 32418922

Group type: EXPERIMENTAL
Intervention: With-sensor group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Without-sensor group
Number of subjects: 124
Study: 34245243

Group type: EXPERIMENTAL
Intervention: ccIIV4
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 727
Study: 32168484

Group type: EXPERIMENTAL
Intervention: Bypass surgery (direct or combined direct/indirect) in SS1+2 subgroup
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nonsurgical cohort SS0 group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nonsurgical cohort SS1+2 group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nonsurgical cohort overall
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bypass surgery in SS0 group
Number of subjects: 79
Study: 616403436

Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg) with carboplatin/paclitaxel
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo with carboplatin/paclitaxel
Number of subjects: 158
Study: 34877238

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined endurance + resistance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 32997219

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment
Number of subjects: 0
Study: 32986265

Group type: EXPERIMENTAL
Intervention: Exercise therapy (6 months of intradialytic exercise)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no exercise therapy)
Number of subjects: 15
Study: 36336274

Group type: EXPERIMENTAL
Intervention: Stress group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 34602438

Group type: EXPERIMENTAL
Intervention: Femitex‐SP4 (500 mg powdered herbs in capsule form, twice daily)
Number of subjects: 150
Study: 34090550

Group type: EXPERIMENTAL
Intervention: PFMT+CTM
Number of subjects: 34

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 34
Study: 32690739

Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant (120 mg vial for <26 weeks GA; 240 mg vial for 26-28 +6 weeks GA) in addition to CPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant
Number of subjects: 0
Study: 36232163

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43
Study: 34185587

Group type: EXPERIMENTAL
Intervention: Intravitreal 1.0 mg risuteganib
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 45
Study: 35458199

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum and Lactobacillus reuteri)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34152273

Group type: EXPERIMENTAL
Intervention: CSLR model with engineered features
Number of subjects: 35

Group type: COMPARATOR
Intervention: CSLR model with basic features
Number of subjects: 35
Study: 34436618

Group type: EXPERIMENTAL
Intervention: Norms module
Number of subjects: 3244

Group type: EXPERIMENTAL
Intervention: Expectancies module
Number of subjects: 3244

Group type: EXPERIMENTAL
Intervention: Other modules
Number of subjects: 3244
Study: 34062418

Group type: EXPERIMENTAL
Intervention: Metformin 3 × 500 mg (group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metformin 3 × 1000 mg (group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 25
Study: 32022282

Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar pegfilgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: US-approved reference biologics
Number of subjects: 0

Group type: COMPARATOR
Intervention: EU-approved reference biologics
Number of subjects: 0
Study: 35124703

Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine-containing chemotherapy (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil)
Number of subjects: 202
Study: 33016132

Group type: EXPERIMENTAL
Intervention: Robot-assisted training (12 sessions at the ARMEO®-Spring)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual occupational and physiotherapy (control group)
Number of subjects: 48
Study: 32580984

Group type: EXPERIMENTAL
Intervention: 8-week Mindfulness-based stress reduction (MBSR) program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 33813084

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (30 μg/kg for 7 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (56 μg/kg for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32044758

Group type: EXPERIMENTAL
Intervention: Full-featured study app
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group with fewer app features
Number of subjects: 328
Study: 36425882

Group type: EXPERIMENTAL
Intervention: Lower-extremity joint manipulation
Number of subjects: 8
Study: 35752785

Group type: EXPERIMENTAL
Intervention: MRI assessment of axillary lymph nodes at baseline, interim, and preoperative time points
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MRI assessment of the most suspicious LN
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MRI assessment of posttreatment nodal status
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MRI diagnosis of ypN0 cases
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) assessment
Number of subjects: 33
Study: 34422246

Group type: EXPERIMENTAL
Intervention: Fast inhalation and slow exhalation (A) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Abdominal breathing (B) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 90
Study: 36067241

Group type: EXPERIMENTAL
Intervention: Mobile application for symptom management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 40
Study: 32804250

Group type: EXPERIMENTAL
Intervention: Novel grading systems for labral tear complexity, labral bruising, labral size, and extent of synovitis.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Existing classification systems for intra-articular lesions.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Labral degeneration classification scheme.
Number of subjects: 5
Study: 32980982

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Adductor canal block combined with IPACK
Number of subjects: 171
Study: 32727706

Group type: EXPERIMENTAL
Intervention: High-risk (HR) nodal fields
Number of subjects: 216

Group type: COMPARATOR
Intervention: Whole mediastinum (WM) fields
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 216
Study: 33737661

Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation (tRNS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 27
Study: 32027167

Group type: EXPERIMENTAL
Intervention: GP40061 insulin glargine (GP‐Gla)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lantus® (Sanofi glargine, Sa‐Gla)
Number of subjects: 180
Study: 35076629

Group type: EXPERIMENTAL
Intervention: OCT and OCTA imaging in ERM group
Number of subjects: 276

Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 276
Study: 33660798

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (alone or in combination with chemotherapy)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 11

Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with chemotherapy
Number of subjects: 11
Study: 33091038

Group type: EXPERIMENTAL
Intervention: Antigen avoidance strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35432822

Group type: EXPERIMENTAL
Intervention: 360° safe indwelling needle
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Routine indwelling needle
Number of subjects: 1000
Study: 33725327

Group type: EXPERIMENTAL
Intervention: Microdose protocol stereoradiography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard low-dose protocol stereoradiography
Number of subjects: 30
Study: 35443809

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1157
Study: 33838757

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 990

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 990
Study: 35122746

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for 6 weeks, 1 hour daily sessions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 60
Study: 33598835

Group type: EXPERIMENTAL
Intervention: Indoor air of PCCs with LaserJet printers
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Indoor air of PCCs with inkjet printers
Number of subjects: 53

Group type: COMPARATOR
Intervention: Indoor air of PCCs (general)
Number of subjects: 53
Study: 32236553

Group type: EXPERIMENTAL
Intervention: Band and plate fixation (plates)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Figure-of-8 wire cerclage (wires)
Number of subjects: 50
Study: 33998255

Group type: EXPERIMENTAL
Intervention: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L)
Number of subjects: 3270

Group type: COMPARATOR
Intervention: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L)
Number of subjects: 3270

Group type: EXPERIMENTAL
Intervention: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Number of subjects: 3270

Group type: COMPARATOR
Intervention: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Number of subjects: 3270
Study: 32445576

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional Stenting (non-DCB)
Number of subjects: 115
Study: 35265146

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sham acupoint catgut embedding (sham ACE)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) in males
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) in females
Number of subjects: 216
Study: 32151791

Group type: EXPERIMENTAL
Intervention: Stroop condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reverse Stroop condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall responses in reverse Stroop condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiments 3 and 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiment 5
Number of subjects: 0
Study: 33565017

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 32
Study: 33196656

Group type: COMPARATOR
Intervention: Genetically predicted BMI of 30 kg/m2
Number of subjects: 55908
Study: 36196872

Group type: EXPERIMENTAL
Intervention: Resilience and Coping for the Healthcare Community (RCHC)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Resilience and Coping for the Healthcare Community expanded version (RCHC+)
Number of subjects: 762
Study: 32910353

Group type: EXPERIMENTAL
Intervention: Free at-home HIV testing
Number of subjects: 151

Group type: COMPARATOR
Intervention: Home Access HIV-1 test kit
Number of subjects: 151
Study: 33578226

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg twice a day starting 24 h after onset of ICH
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo starting 72 h after onset of ICH
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups received intermittent pneumatic compression stockings
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Enoxaparin group
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study: 32352351

Group type: EXPERIMENTAL
Intervention: Ambar Universal APS (AMB-APS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambar Universal (AMB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU)
Number of subjects: 0
Study: 36191863

Group type: EXPERIMENTAL
Intervention: Large gaze duration (80% of conversation time)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Small gaze duration (20% of conversation time)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Patients with SAD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 62
Study: 34495988

Group type: EXPERIMENTAL
Intervention: ChAd63 CAT vaccine (three-antigen: CSP, AMA1, ME-TRAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ChAd63 CA vaccine (two-antigen: CSP, AMA1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 40
Study: 33012603

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 0
Study: 35045323

Group type: EXPERIMENTAL
Intervention: Planful, Healthful and Frequent Family Evening Meals (C3)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Family Evening Meals with Fast Food (C2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Unplanned Infrequent Family Evening Meals with Mixed Healthfulness (C1)
Number of subjects: 114
Study: 34057392

Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0
Study: 32559602

Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 155
Study: 35798178

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 101
Study: 33955262

Group type: EXPERIMENTAL
Intervention: Endurance exercise (cycling)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Resistance exercise (leg-extension)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Four weeks of exercise training (END and RT)
Number of subjects: 34
Study: 32273162

Group type: EXPERIMENTAL
Intervention: PGT‐A group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35168962

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination of desmopressin and VWF-containing concentrate
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (prophylaxis)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Desmopressin (bleeding episodes)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (bleeding episodes)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Desmopressin (medical procedures)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (medical procedures)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination of desmopressin and VWF-containing concentrate (medical procedures)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 123
Study: 33761651

Group type: EXPERIMENTAL
Intervention: Real ear acupuncture once a week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham ear acupuncture once a week for 8 weeks
Number of subjects: 0
Study: 35248123

Group type: EXPERIMENTAL
Intervention: Clinical monitoring alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory and clinical monitoring
Number of subjects: 0
Study: 33629185

Group type: EXPERIMENTAL
Intervention: Higher waist circumference (WC)
Number of subjects: 127997

Group type: EXPERIMENTAL
Intervention: Higher waist-to-hip ratio (WHR)
Number of subjects: 127997